DR. EDWARD KAVALERCHIK, M.D.
Osteopathic Medicine in San Diego, CA
License number
California A87968
Category
Osteopathic Medicine
Type
Medical Oncology
License number
California A87968
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
California A87968
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
3350 111-E Va Sd La Jolla Medical Ctr, San Diego, CA 92161
Phone
(858) 642-3356
Personal information
See more information about EDWARD KAVALERCHIK at radaris.comName
Address
Phone
240 Santa Paula Ave, San Francisco, CA 94127
5130 La Jolla Blvd #3K, San Diego, CA 92109
Professional information
Edward Kavalerchik, La Jolla CA
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Scripps Clinic, Green Hospital
10666 N Torrey Pines Rd, La Jolla, CA 92037 San Diego Veterans Affairs Medical Center
3350 La Jolla Village Dr, San Diego, CA 92161
10666 N Torrey Pines Rd, La Jolla, CA 92037 San Diego Veterans Affairs Medical Center
3350 La Jolla Village Dr, San Diego, CA 92161
Education:
Stony Brook University (2002)
Dr. Edward Kavalerchik, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Age:
50
Address:
La Jolla Office
10666 N Torrey Pines Rd, La Jolla 92037
(800) 727-4777 (Phone), (858) 554-8065 (Fax)
3350 La Jolla Village Dr SUITE 111-E, San Diego 92161
(858) 642-3356 (Phone)
10666 N Torrey Pines Rd, La Jolla 92037
(800) 727-4777 (Phone), (858) 554-8065 (Fax)
3350 La Jolla Village Dr SUITE 111-E, San Diego 92161
(858) 642-3356 (Phone)
Certifications:
Internal Medicine, 2005, Medical Oncology, 2009
Awards:
Healthgrades Honor Roll
Languages:
English, Russian
Education:
Medical School
State University of New York / Health Science Center At Stony Brook
Graduated: 2002
Uc San Diego
State University of New York / Health Science Center At Stony Brook
Graduated: 2002
Uc San Diego
Edward Kavalerchik, San Diego CA
Specialties:
Internist
Address:
3350 La Jolla Village Dr, San Diego, CA 92161
Education:
State University of New York, School of Medicine (Stony Brook) - Doctor of Medicine
UCSD Healthcare - Fellowship - Oncology (Internal Medicine)
UCSD Healthcare - Residency - Internal Medicine
UCSD Healthcare - Internship - Internal Medicine
UCSD Healthcare - Fellowship - Oncology (Internal Medicine)
UCSD Healthcare - Residency - Internal Medicine
UCSD Healthcare - Internship - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Wnt Pathway Mutations In Cancer Stem Cells
US Patent:
2010028, Nov 11, 2010
Filed:
Nov 2, 2007
Appl. No.:
12/447884
Inventors:
Catriona Helen M. Jamieson - La Jolla CA, US
Ifat Geron - San Diego CA, US
Annelie Abrahamsson - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
Irving L. Weissman - Stanford CA, US
Jason Gotlib - Stanford CA, US
Ifat Geron - San Diego CA, US
Annelie Abrahamsson - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
Irving L. Weissman - Stanford CA, US
Jason Gotlib - Stanford CA, US
International Classification:
C12Q 1/48, C12Q 1/68, G01N 33/573, A01K 67/00
US Classification:
800 10, 435 15, 435 6, 435 74
Abstract:
Cancer specific splicing events in the Wnt/β-catenin signaling pathway are associated with progression of myelogenous leukemia. Misspliced genes of interest include GSK3β. In some embodiments of the invention, polynucleotides are provided that correspond to misspliced GSK3β transcripts associated with cancer. Such transcripts are characterized by a deletion of exon (8), and particularly in exon (8) and (9). Detection of such transcripts in cells is indicative of the presence of leukemia, and particularly of the presence of leukemia stem cells. In other embodiments, polypeptides are provided that are encoded by misspliced GSK3β transcripts associated with cancer. Such polypeptides are useful as diagnostic markers for cancer, and as a target for screening of therapeutic agents. Animal models comprising a human LSC having a misspliced GSK3b transcript provide a useful model for leukemia, for drug/gene screening in the prevention and treatment of leukemia in humans, etc.
Models Of Erythropoiesis
US Patent:
2011024, Oct 6, 2011
Filed:
Oct 24, 2007
Appl. No.:
12/446203
Inventors:
Catriona Helen M. Jamieson - LaJolla CA, US
Ken Kaushansky - Del Mar CA, US
Charlene Barroga - San Diego CA, US
Ifat Geron - San Diego CA, US
Annelie Schairer - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
Ken Kaushansky - Del Mar CA, US
Charlene Barroga - San Diego CA, US
Ifat Geron - San Diego CA, US
Annelie Schairer - San Diego CA, US
Edward Kavalerchik - San Diego CA, US
International Classification:
A01K 67/033, A61K 49/00, C12Q 1/02
US Classification:
424 92, 800 9, 435 29
Abstract:
Non human animal models are provided for diseases involving erythroid function, particularly myeloproliferative disease. The models are useful for testing and screening of biologically active agents that affect erythropoiesis, and erythroid function. In the animal models of the invention, a hematopoietic stem or progenitor cell (HSC) population that has been genetically altered by the introduction of a mutant JAK2 coding sequence is transplanted into an immunocompromised, xenogeneic, non-human recipient. The recipient animal is engrafted with the cell population at a high frequency, and develops a myeloproliferative disorder characterized by polycythemia.
Clinical Scholar At The Scripps Research Institute
Position:
Clinical Scholar at The Scripps Research Institute
Location:
Greater San Diego Area
Industry:
Research
Work:
The Scripps Research Institute
-
Clinical Scholar